Bionano Genomics, Inc. (BNGO) key performance indicators and operating metrics (7 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Non-GAAP Gross Margin | 49.00 percent | FY2026-Q1 |
| Nano-Channel Array Flow Cells Sold | 8.18K | FY2026-Q1 |
| Optical Genome Mapping Installed Base | 387.00 | FY2025-Q4 |
| New Optical Genome Mapping Systems Installed | 9.00 | FY2025-Q4 |
| Adjusted Operating Expense | 9.7M | FY2025-Q3 |
| Total Revenue (Low End/High End) | 7.4M | FY2025-Q3 |
| Peer-Reviewed Publications | 97.00 | FY2025-Q3 |
Back to BNGO overview · BNGO earnings · BNGO holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.